| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | 0.16 | 5e-06 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | 0.16 | 8e-06 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.16 | 9e-06 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-05 |
| mRNA | BHG712 | GDSC1000 | pan-cancer | AAC | 0.13 | 2e-05 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.16 | 2e-05 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-05 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | 0.15 | 2e-05 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 3e-05 |
| mRNA | AS605240 | GDSC1000 | pan-cancer | AAC | 0.14 | 3e-05 |